Dapansutrile – (54863-37-5)

Dapansutrile is a potent, orally active, and selective NLRP3 inflammasome inhibitor with anti-inflammatory properties. It works by binding to the NLRP3 protein, inhibiting the formation of the NLRP3 inflammasome, and reducing the production of pro-inflammatory cytokines such as IL-1β and IL-18.

This mechanism makes it a potential therapeutic candidate for inflammatory diseases, including gouty arthritis, osteoarthritis, and neurodegenerative conditions like multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. Dapansutrile has shown efficacy in preclinical models and is currently undergoing clinical trials for various inflammatory and autoimmune conditions.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Dapansutrile
https://pubchem.ncbi.nlm.nih.gov/compound/12714644
https://www.medchemexpress.com/Dapansutrile.html
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/dapansutrile